Vecura Biotech Insiders #03: Building a Humanized Tyrosinase Model for Structure-Based Docking

A User-Shared Workflow from the Vecura Community

In structure-based discovery, the quality of the target model can shape every result that follows.

For some targets, researchers can start from a high-resolution experimental structure. For others, especially human proteins without available crystal or cryo-EM structures, the first challenge is building a model that is biologically meaningful enough to support downstream analysis.

In this third edition of Vecura Biotech Insiders, we highlight a workflow shared with the Vecura team by Thanh Tran during the support process.

The workflow focuses on human tyrosinase, or TYR, a copper-dependent enzyme involved in melanin biosynthesis. Human TYR is pharmacologically important, but according to the user-shared workflow, it does not yet have an experimental crystal structure available in the Protein Data Bank. As a result, many published inhibitor screening workflows rely on mushroom tyrosinase as a surrogate model.

Thanh's workflow takes a different route: starting from the AlphaFold model of human TYR, transplanting the catalytic copper ions from the mushroom tyrosinase structure, preparing the copper-tagged system, and validating the model through docking of a small compound panel.

The goal is not to claim that this model replaces experimental structure determination. The goal is to show how a careful computational workflow can create a more human-relevant structural basis for tyrosinase docking.

Research Context: Why the Human Target Matters

Tyrosinase is a key enzyme in melanin biosynthesis. It catalyzes the hydroxylation of L-tyrosine to L-DOPA and the oxidation of L-DOPA to dopaquinone, a rate-limiting step in melanin formation.

Human TYR is associated with several biological and medical contexts:

However, the structural biology presents a challenge.

The workflow notes that human TYR does not currently have an experimental X-ray or cryo-EM structure in the Protein Data Bank. Because of this, many studies use Agaricus bisporus mushroom tyrosinase or polyphenol oxidase structures as a surrogate.

That surrogate is useful, but imperfect. The workflow highlights several reasons why mushroom tyrosinase may not fully represent the human ortholog:

This is why a humanized model is useful for structure-based docking.

Workflow Overview: From AlphaFold to Copper-Tagged Human TYR

The workflow followed a staged modeling and validation path:

Figure 1. Workflow template showing target mapping, structure prediction, structure validation, and structure preparation.

This workflow shows how the target model itself becomes part of the scientific work. Before docking inhibitors, the user first built and audited the receptor model.

Tools and Structures Used in the Workflow

The key methodological move was copper tagging. AlphaFold does not provide metal ions in the model, but TYR requires a binuclear copper center for catalytic relevance. The workflow solved this by transplanting CuA and CuB coordinates from the aligned mushroom structure into the human AlphaFold model.

Stage 0: Defining the Human TYR Model

Before any docking or simulation, the workflow first framed the TYR sequence and domain architecture.

Human TYR, based on the workflow, is a 529-amino-acid type-I membrane glycoprotein. For modeling and docking, the workflow focused on the luminal catalytic domain.

The active site was defined by six histidines coordinating two copper ions:

This active-site definition became the anchor for the rest of the workflow.

Stage 1-2: Auditing the AlphaFold Model Against Mushroom TYR

The workflow then fetched the AlphaFold model of human TYR and compared it against the mushroom tyrosinase/PPO3 reference structure.

The human catalytic domain was superimposed onto the equivalent catalytic domain of PDB 2Y9X. This allowed the user to inspect whether the AlphaFold backbone placed the six copper-coordinating histidines in a geometry compatible with the type-3 copper center.

This step also helped identify differences in the substrate-access channel, including gatekeeper residue divergence between mushroom and human TYR. This matters because active-site access can influence docking behavior.

In other words, this stage was not only about aligning two structures. It was about asking whether the human AlphaFold model could be made chemically meaningful for docking.

Stage 3: Copper Tagging by Structural Transplant

This was the methodological core of the workflow.

The user transplanted the two copper ions from PDB 2Y9X into the aligned human TYR model. The workflow applied the same rigid transformation used in the structure alignment to place CuA and CuB into the human active site.

After copper placement, the geometry was checked against expected coordination ranges.

The workflow reported the following model quality values:

Figure 2. Human Tyrosinase model (left) and Mushroom Tyrosinase model (right).

These values suggest that the transplanted metal geometry was internally consistent in this workflow, although the model remains computational and should not be treated as experimentally resolved.

Stage 4-5: Preparing and Benchmarking the System

After copper tagging, the system was prepared in OpenMM.

The workflow described solvation in a TIP3P water box, ion addition to neutralize charge and approximate physiological ionic strength, AMBER ff14SB for the protein, and custom bonded parameters for the Cu-His cage.

Energy minimization was performed in staged cycles with tapering positional restraints:

The goal was to relieve structural strain while preventing distortion of the metal-binding cage.

The workflow also described an optional or planned MD benchmarking stage. During MD, the key tracked signals included:

Running the same protocol on the mushroom reference system provides a benchmark for whether the copper-tagged human model behaves reasonably relative to a crystallographically characterized structure.

Stage 6: Docking Validation with a Six-Compound Panel

The workflow then used gnina for docking validation, combining Vina scoring with CNN-derived rescoring.

Instead of centering the docking box on the tropolone ligand, the workflow centered it on the midpoint of the two copper ions. This was intentional, because the copper center defines the catalytic site.

The compound panel included natural substrates and known TYR inhibitors:

The reported human TYR docking outputs were:

The workflow emphasized that these scores should be interpreted carefully. Substrates may not top the Vina ranking because Vina scores can favor molecular size and hydrophobic contacts. Cu-chelating inhibitors may also be under-scored because classical docking functions may not fully capture direct copper coordination.

What This Workflow Demonstrates

This workflow demonstrates three important lessons for structure-based modeling and docking.

The key insight is that the workflow does not begin with docking. It begins with target preparation.

For human tyrosinase, that means defining the catalytic domain, auditing AlphaFold confidence, transplanting the binuclear copper center, minimizing the system, benchmarking its geometry, and only then docking ligands.

Why Vecura Helps

For structure-based workflows, researchers often need to connect multiple steps across different tools and assumptions. Each step can affect the reliability of the final docking result.

Vecura helps reduce this friction by supporting connected workflows where users can move from target mapping to structure prediction, validation, preparation, simulation, and docking.

The value of Vecura in this workflow is not a single docking score. It is the ability to organize a defensible modeling path from a human protein sequence to a copper-tagged receptor model and docking-ready workflow.

A Note on Scientific Interpretation

This workflow is computational and should be interpreted as an exploratory in-silico modeling workflow, not as an experimentally validated human TYR structure.

The copper ions were transplanted from a mushroom reference structure rather than experimentally observed in human TYR. The copper model uses fixed-charge or dummy-atom approximations and cannot fully capture type-3 di-copper redox chemistry. Docking scores from gnina should not be read as absolute binding affinities, Kd values, or IC50 values.

The workflow also omits glycosylation, the transmembrane anchor, and the melanosomal membrane context. These omissions may be acceptable for active-site docking exploration, but they matter for full-length enzyme behavior and folding biology.

The value of this workflow lies in its transparency: it makes the modeling assumptions visible and provides a structured path for benchmarking, docking, and further validation.

Where the Workflow Goes Next

The workflow suggests several next steps for further validation and refinement:

Until an experimental human TYR structure becomes available, a carefully copper-tagged and transparently caveated AlphaFold-based model can provide a practical structural basis for human TYR-targeted docking.

Try Structure-Based Docking Workflows on Vecura

Thanh's workflow highlights a practical principle for structure-based discovery:

Do not start docking too early.
Prepare the target.
Check the active site.
Account for missing cofactors.
Benchmark the model.
Interpret scores with mechanism in mind.

Bring your target to Vecura and build structure-based docking workflows with clearer assumptions, connected tools, and transparent validation steps.